Graves disease
Conditions
Interventions
Efficacy Prediction Model Cohort:None
Image-Pathology Feature Extraction Cohort:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Image-Pathology Feature Extraction Cohort 1. Patients definitively diagnosed with GD based on clinical and laboratory examinations; 2. Patients who underwent a thyroidectomy, with complete thyroid tissue pathological specimens obtained postoperatively; 3. Patients who completed both thyroid ultrasound and radionuclide imaging within one week prior to surgery; 4. Control group requirements: Patients pathologically diagnosed with thyroid microcarcinoma (nodule diameter < 1 cm) coexisting with Hashimoto's thyroiditis, who completed both ultrasound and radionuclide imaging within one week prior to surgery. Efficacy Prediction Model Cohort 1. GD patients are explicitly diagnosed in accordance with the 131I Guidelines for the Treatment of Graves disease(2021 edition) of the Nuclear Medicine Branch of the Chinese Medical Association; 2. GD patients who have received Iodine-131 therapy at the study center.
Exclusion criteria
Exclusion criteria: Image-Pathology Feature Extraction Cohort 1. Patients with missing pathological specimens, inadequate tissue fixation, or poor staining quality that preclude immunohistochemical (IHC) analysis and cell count assessment; 2. Patinets with incomplete imaging, poor image quality, or artifacts that prevent standardized Region of Interest (ROI) extraction or quantitative analysis. Efficacy Prediction Model Cohort 1. Patients with missing or incomplete imaging data, including the absence of pre-treatment ultrasound or radionuclide imaging, or cases where the time interval between the imaging examination and Iodine-131 therapy exceeds the predefined window, rendering the images unrepresentative of the pre-treatment baseline status; 2. Patients who are lost to follow-up or have incomplete follow-up data, including failure to complete the standardized follow-up assessment for thyroid heterogeneity at 3 to 6 months post-treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| thyroid fuction;Percentage of positive cells;Staining intensity; | — |
Countries
China
Contacts
Public ContactBin Liu
West China Hospital of Sichuan University
Outcome results
None listed